De Luca, R.; Vitale, P.; Pepe, A.; Spedaliere, R.; Simonato, A.; Addeo, R.; Cicero, G.
Avelumab in First Line Maintenance in Advanced Urothelial Carcinoma (aUC) in Elderly Patients: Efficacy, Tolerability, and Quality of Life in Real Life Setting. Sci. Pharm. 2024, 92, 62.
https://doi.org/10.3390/scipharm92040062
AMA Style
De Luca R, Vitale P, Pepe A, Spedaliere R, Simonato A, Addeo R, Cicero G.
Avelumab in First Line Maintenance in Advanced Urothelial Carcinoma (aUC) in Elderly Patients: Efficacy, Tolerability, and Quality of Life in Real Life Setting. Scientia Pharmaceutica. 2024; 92(4):62.
https://doi.org/10.3390/scipharm92040062
Chicago/Turabian Style
De Luca, Rossella, Pasquale Vitale, Alessio Pepe, Roberta Spedaliere, Alchiede Simonato, Raffaele Addeo, and Giuseppe Cicero.
2024. "Avelumab in First Line Maintenance in Advanced Urothelial Carcinoma (aUC) in Elderly Patients: Efficacy, Tolerability, and Quality of Life in Real Life Setting" Scientia Pharmaceutica 92, no. 4: 62.
https://doi.org/10.3390/scipharm92040062
APA Style
De Luca, R., Vitale, P., Pepe, A., Spedaliere, R., Simonato, A., Addeo, R., & Cicero, G.
(2024). Avelumab in First Line Maintenance in Advanced Urothelial Carcinoma (aUC) in Elderly Patients: Efficacy, Tolerability, and Quality of Life in Real Life Setting. Scientia Pharmaceutica, 92(4), 62.
https://doi.org/10.3390/scipharm92040062
